Exploring U.S. Patent 5, 106,616 – Administration of Acemannan
An Entire Research Program Inside a Single Patent
This video begins our exploration of two significant United States patents—both centered on Acemannan.
Now, Acemannan itself cannot be patented. It is a compound found in nature. No scientist invented it. No company created it. It was already there. God made it—and that settles that.
But scientists can discover something new about a naturally occurring compound. They can discover how to isolate it, stabilize it, prepare it, administer it, or use it in ways that were not previously known. And when those discoveries are new, useful, and sufficiently inventive, they can become the basis for patent protection
And that is what makes these two patents so interesting.
We will work our way through these two patents—not merely asking what was patented, but examining what the researchers discovered, what they did with Acemannan, and why they believed those discoveries were important enough to protect.
It will take us a little time, but that’s what we do here.
We dig deeper and reach wider.
Of the two patents we will be covering the first one is Patent 5,106,616 — Administration of Acemannan
The Patent That Asked: What Does Acemannan Actually Do?
This patent Administration of Acemannan, was issued April 21, 1992, to three inventors: Bill H. McAnalley, Robert H. Carpenter, and Harley R. McDaniel.
The patent document before us is 51 pages long.
It contains 25 numbered figures, 21 tables, and 28 examples.
Think about that for a moment.
This does not read like someone discovered an interesting ingredient in aloe vera one afternoon and rushed out to make a claim about it.
It reads more like an entire research program packed inside a single patent.
And that is what I want to help you appreciate.
We cannot possibly examine every experiment in detail in this single presentation, and we don’t need to. My goal is much simpler.
By the time we’re finished, I want you to have a pretty good understanding of what these scientists were investigating, what they believed they were seeing, and why Acemannan attracted so much scientific attention.
Figure 1 — What is inside an Aloe vera leaf? Focusing especially on the inner leaf gel, the mucilage.
Figure 2 — Separating the leaf to get to the gel
Before the patent shows us what Acemannan does, the inventors first show us where it comes from. Figures 1 and 2 take us inside the Aloe vera leaf. They distinguish the outer rind and yellow latex from the clear inner gel. That distinction matters because the story we’re about to follow begins with the polysaccharide-rich material found within that inner gel.
Figures 3 through 10 take us directly into immune biology.
Several of these experiments examine IL-1.
Others look at lymphocytes.
Others examine cooperation between monocytes and T cells.
You do not need to remember those technical names.
Remember the idea:
Acemannan was not being treated as a passive ingredient. Researchers were looking for measurable changes in immune-cell behavior when Acemannan was present.
We might call these signaling molecules biological text messages. One cell detects something, releases a signal, and other cells receive information that can influence what happens next.
And the patent didn’t stop with communication.
It examined phagocytosis.
That is simply the ability of certain immune cells to surround, engulf and dispose of unwanted material.
The patent’s discussion concludes from these experiments that Acemannan enhanced macrophage phagocytosis under the conditions tested.
Now stop and think about what is happening.
We started with a polysaccharide from aloe: Acemannan
And already the questions have moved into:
immune-cell activation,
chemical signaling,
T-cell response,
and phagocytosis.
And we’re only getting started.
The patent then turns its attention to fibroblasts—cells that play an important role in rebuilding connective tissue and repairing wounds. And it asks two very different questions about them.
Does Acemannan encourage these repair-related cells to multiply? The patent reports that Acemannan extract had been observed to increase fibroblast proliferation, in some instances two to three times over control, although the results varied among samples.
Does Acemannan damage these cells? “The researchers compared the Acemannan-containing preparation with several established topical wound-care products: Betadine, an over-the-counter iodine-based antiseptic; Hibiclens, an over-the-counter chlorhexidine antiseptic cleanser; and Granulex, a prescription wound-treatment spray used to help remove damaged tissue and promote healing.” Granulex brand has since been discontinued in the United States
Figure 11 looks at cell injury over time. Acemannan shows very little cell injury over time, unlike the conventional wound-cleansing agents. Figure 12 looks at what happens as concentrations increase. Acemannan maintains low cytotoxicity as its concentration increases, while comparison agents become increasingly damaging. Figure 13 provides another comparison under additional treatment conditions. Acemannan does not damage the fibroblasts itself, although, in this experiment, it does not protect them from the damaging effects of the other toxic agents.
So the story here is remarkably straightforward: So did Acemannan encourage repair-related cells to proliferate? Yes. Did Acemannan harm those same cells. no
That actually makes Figures 11–13 more interesting, because the comparison wasn’t Acemannan versus three arbitrary chemicals. These were already approved products used in skin or wound care, and the experiment was asking what happened when human fibroblasts—the very cells involved in tissue repair—were exposed to them.
But this raises an obvious question. It’s one thing for Acemannan to appear remarkably non-toxic to cells growing in a laboratory dish. But What happens when you put it into a living animal—and continue administering it over time?
The patent addresses that question too. Researchers conducted longer-term toxicity studies in both dogs and rats. And once again, the finding that stands out is what they did not find: evidence of toxicity.
INCLUDE DOG AND RAT GRAPHIC HERE.
The animal studies extend the safety story beyond the laboratory dish. In dogs, Acemannan was given orally for 91 days at doses of 825 milligrams per kilogram of body weight per day, with no toxic effects reported. To put that into perspective, for a 50-pound dog (for instance: a female black lab) that would equal about 18.7 grams of Acemannan per day—the equivalent of roughly 94 capsules containing 200 milligrams each. In rats, the researchers measured the dose differently because Acemannan was mixed directly into the feed. The highest level was 38,475 parts per million, which means about 38.5 milligrams of Acemannan in every gram of food. So, for example, if a rat ate 20 grams of that feed in a day, it would consume about 769 milligrams of Acemannan—and even at that dietary concentration over 180 days, the patent reports “no clinical, gross pathological, or toxic effects.”
This toxicity issue was exactly why Acemannan was rejected as a drug by the Food and Drug Administration
LD refers to lethal dose. In drug testing, researchers must show an LD50—the dose that kills 50% of test animals—and an LD100—the dose that kills all of them, with a safe margin between the two for human use. Strange as it sounds, establishing how much is lethal is part of establishing what is considered safe. No matter how much Acemannan was tested, no lethal dose could be established. While that seemed like a breakthrough, in this case FDA drug approval required demonstrable toxicity. Because Acemannan showed none, the FDA rejected the Acemannan investigative new drug application.
And then the patent makes another significant transition. Up to this point, much of what we’ve examined has involved laboratory cells, immune activity, and experimental models. But Figures 14 through 19 take us somewhere different: human beings living with HIV. These figures come from retrospective observations of HIV-positive patients who had been prescribed an aloe Acemannan preparation. The researchers followed several indicators. These were not randomized, placebo-controlled clinical trials, so we need to be careful about what conclusions we draw. But their inclusion is significant because the patent has now moved from asking what Acemannan does in the laboratory to asking what researchers were observing in actual HIV patients.
“Don’t worry about trying to decipher every line on these six graphs. They essentially ask three questions: What happened to the patients’ T4 immune cells? What happened to their overall clinical condition? And what happened to a measurable marker of HIV?”
- Figure 14 —Acemannan treatment was associated with increasing T4 helper-cell counts over time. The patent reports the average rising from 355 initially to 489 at 350 days among patients with available data.
- Figure 15— A second patient group also showed an increase in average T4 helper-cell counts, from 217 initially to 259 after 90 days.
- Figure 16 —— Patient clinical scores declined over time, and get this: with lower scores representing improvement: from an average 5.6 initially to 1.5 at 350 days in the first group.
- Figure 17 —— Researchers predicted beforehand which HIV patients were more likely—or less likely—to respond. After 90 days, both groups showed improvement, but the group predicted to do well improved considerably more. Remember: on this scale, lower was better.
- Figure 18 —— Fewer patients had detectable HIV core antigen in their blood as time went on. This antigen was a marker of HIV activity, so the downward trend suggested less detectable viral activity in the group. However, the patent cautions that the change was not statistically significant, meaning the researchers could not confidently rule out chance as the explanation.
- Figure 19 —— The second study group showed a similar pattern suggesting decreasing serum core antigen, again without a statistically significant difference.
The patent next describes Example 22, an exploratory clinical pilot study of Acemannan in inflammatory bowel disease, which included Crohn’s disease and ulcerative colitis. Nine patients were treated with 200 mg of Acemannan daily in capsule form. And for reference sake the PhD who processes our Acemannan takes 7 x 200mg capsules daily. These patients had symptoms that had previously been nonresponsive to conventional agents.
- Figure 20 — What Happened to the Patients’ Symptoms?
This is the clinical symptom score. The researchers counted things patients were actually experiencing—diarrhea, blood in the stool, excess mucus, abdominal pain, cramping, and related symptoms. The score ranged from 0 to 7, with 0 meaning asymptomatic. Figure 20 compares those scores before treatment of Acemannan with the best response recorded during Acemannan therapy. The scores went from a low of 3 to a high of 7 down to a low of zero to a high of 2. 7 of the 9 were at zero. - Figure 21 — What Did Doctors See Inside the Colon?
This moves beyond what the patients reported and looks at endoscopic findings— what the physician could visibly see when examining the inside surface of the colon with an endoscope. They scored findings such as ulceration, redness, exudate (exudate is the fluid and inflammatory material that can collect on the surface of irritated or damaged tissue), and other visible abnormalities on a 0-to-5 scale, again with 0 representing no abnormal findings. Of the nine only two submitted to both endoscope evaluations. The two went from 3 and 5 down to a 1. - Figure 22 — What Did the Tissue Biopsies Show?
Figure 22 goes one level deeper, looking microscopically at the bowel tissue itself. Researchers evaluated findings such as ulcerated mucosa, edema, inflammatory cells, granulomas, crypt abscesses, and fibrosis. This was intended to ask whether the tissue-level evidence of inflammation changed as well. 8 of the 9 submitted to the microscopic exam. 4 of the 8 had a score of 5; and the remaining had a score of 7. No one submitted to biopsy exam a second time around. In light of that, the strongest follow-up evidence here is clinical rather than tissue-based, because most patients declined repeat invasive procedures once they were feeling better. Feeling better is what the real objectives of these people were anyway. - Figure 23 — Putting the Patient Results Together
Figure 23 is the summary chart for the pilot study, bringing together each patient’s treatment dates and dosage along with the clinical, endoscopic, and tissue-based scores.
One of My Favorite Experiments: Where in the World Did the Acemannan Go?
Then we arrive at Example 23.
And I think this one deserves special attention. There were no tables or graphics with this one.
Researchers actually used carbon-14-labeled Acemannan.
In plain language, they gave the Acemannan a detectable radioactive label so they could track it.
Then they exposed human monocytes and macrophages to it.
Their question was beautifully simple:
Do these cells, these monocytes and macrophages, actually take Acemannan up into themselves? If you’ve noticed other videos at this website you know such a claim has been made and now here is some hard evidence.
The patent reports a yes to this question with measurable uptake.
The highest measured uptake occurred at about 48 hours.
And when the researchers measured what had happened, they found something remarkable: the Acemannan wasn’t simply floating arbitrarily around the cells. The cells, the monocytes and macrophages, had taken Acemmannan in and accumulated it internally at levels far greater than what remained in the surrounding solution. 760 times greater concentration than what was in the surrounding area. these immune cells weren’t just exposed to Acemannan—they were taking it in and concentrating it inside themselves.
Vaccines
Then Acemannan was tested as a possible vaccine adjuvant.
An adjuvant is simply something added to, or used with, a vaccine to strengthen the immune response to the vaccine antigen.
In poultry experiments, the researchers examined antibody responses when Acemannan was included with an infectious bursal disease vaccine.
One study showed a stronger antibody response.
A second study encountered experimental problems and produced less consistent results.
So, positive findings, and some limitations,
Another video exists at this website relative to vaccines in poultry, it can be found at the link in the transcription below.
The Patent in One Screen
I did not cover them all. And I am not going to read them all.
You can pause the video if you want to examine them.
But just scan the subjects:
immune signaling,
macrophages,
T cells,
phagocytosis,
tumor cells,
HIV,
viral glycoproteins,
fibroblasts,
wound healing,
human patient observations,
inflammatory bowel disease,
cellular uptake of Acemannan,
vaccines
That is what I mean by breadth.
This patent is not one experiment.
It is not one disease.
It is not one biological pathway.
It feels more like a collection of interconnected scientific studies built around one central question:
What happens biologically when Acemannan is administered?
And the answer the inventors kept encountering was that Acemannan appeared to interact with systems involved in immune recognition, communication and response.
It doesn’t mean every experiment carried equal weight.
Some were laboratory experiments.
Some involved animals.
Some were small human investigations.
Some were case observations.
Some examples merely explained how Acemannan could be formulated and administered.
Twenty-five figures. Twenty-one tables. Twenty-eight examples. Fifty-one pages.
For one molecule.
For one patent.
This got the ball rolling in a significant way to take it to market.
“What is Patent 5,106,616 about?”
It is the patent in which McAnalley, Carpenter and McDaniel laid out a broad body of evidence concerning the administration and biological activity of Acemannan.
They examined what happened to immune cells.
They measured signaling.
They examined phagocytosis.
They investigated viruses.
They looked at tumor-cell responses.
They followed wounds.
They examined human patient data.
They studied inflammatory bowel disease.
They tracked Acemannan into macrophages.
They tested vaccine responses.
And every answer seemed to turn the light on a little brighter
The patent essentially puts Acemannan into discussion across six major arenas:
HIV/AIDS and viral disease → inflammatory bowel disease → wound healing → cancer/tumors → immune dysfunction → neurological/autoimmune disease.
Underneath those sit a dozen specific disease conditions. And under that a couple dozen more maladies. All mentioned inside the patent narrative.
That breadth is significant because (please hear me on this) the inventors were not proposing that Acemannan independently “cures” all these diseases. Their unifying idea was different: they believed Acemannan was acting upon host-defense mechanisms—Acemannan was acting particularly upon what is an innate biological part of the human body: monocytes/macrophages, IL-1 production, phagocytosis, antibody production, natural-killer-cell activity. All the systems you want functional. The patent’s abstract lays out that mechanistic theme very clearly. And I have included a paraphrase of it at the end of this video.
This is a point that we have been trying to drive home in the last few dozen videos at this website. Acemannan doesn’t go to work to fight disease as much as it goes to work on behalf of what is already built-in to the biological systems of the human body so that it can fight disease more effectively. And it does so with no toxicity or side effects. Think about this for just one precious minute. How much physiological recovery potential resides naturally in the human body that if we gave it a chance and/or knew of a non-toxic way to optimize that potential that we would be better off and even delighted by the results?
Which takes us directly to the next patent.
Because once scientists believe they have identified a substance capable of influencing something as fundamental as the immune response, the obvious next question becomes:
Where might those biological effects matter?
And that brings us to Patent 5,308,838 which we will cover in the next video, where the very first sentence of this patent announces: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient’s immune system. This generates the obvious question: “What conditions would that be that need the immune system for proper recovery and resolution?
I hope you will always be careful to maintain good works to meet urgent needs and become heroes to your generation.
Paraphrase of Abstract Patent 5,106,616
Acemannan was found to strongly stimulate certain immune cells—especially monocytes and macrophages—to produce important signaling substances called interleukin-1 (IL-1) and prostaglandin E2 (PGE2). These signals can influence other cells involved in immune response and tissue repair, including T cells, B cells, fibroblasts, and cells that line blood vessels.
The patent also reports that Acemannan showed no demonstrated toxicity in the systems studied and appeared to act as an immune enhancer. In addition to stimulating IL-1 and PGE2 production, it was reported to increase phagocytosis—the process by which immune cells engulf unwanted material—support antibody production, and increase antiviral activity in the blood. In patients with AIDS/ARC, the patent further reports that Acemannan was associated with the production of defective HIV particles.
The patent also describes Acemannan as affecting virus production in vaccine cultures, enhancing the immune response to viral vaccines in chickens, and showing antitumor activity against sarcoid tumors in horses.